论文部分内容阅读
索拉非尼是一种口服多激酶抑制剂,为一新的多靶点抗肿瘤药,主要抑制肿瘤血管形成及肿瘤细胞增殖。索拉非尼已被批准用于治疗晚期肾细胞癌,对其他癌症的作用也正在研究中。目的:对索拉非尼治疗晚期肾细胞癌的不良反应进行归纳总结,以便于更广泛深入地了解该药,为临床合理用药提供参考。方法:从皮肤不良反应、消化系统不良反应、心血管系统不良反应、全身症状等方面进行观察分析。结果及结论:索拉非尼不良反应轻微,常见有皮疹、手足综合征、乏力、腹泻等,心血管系统不良反应虽较少,但应引起重视。
Sorafenib is an oral multi-kinase inhibitor, a new multi-targeted anti-tumor drug that mainly inhibits tumor angiogenesis and tumor cell proliferation. Sorafenib has been approved for the treatment of advanced renal cell carcinoma, and the effects on other cancers are also under study. Objective: To summarize the adverse reactions of sorafenib in the treatment of advanced renal cell carcinoma in order to understand the drug more extensively and provide reference for clinical rational drug use. Methods: From skin adverse reactions, adverse reactions of the digestive system, cardiovascular system adverse reactions, systemic symptoms were observed and analyzed. RESULTS AND CONCLUSION: Sorafenib had mild adverse reactions, such as rash, hand-foot syndrome, fatigue, diarrhea and so on. There were fewer adverse reactions in the cardiovascular system, but attention should be paid to it.